Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
AstraZeneca
M.D. Anderson Cancer Center
University of Washington
SWOG Cancer Research Network
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
SWOG Cancer Research Network
Dana-Farber Cancer Institute
European Organisation for Research and Treatment of Cancer - EORTC
M.D. Anderson Cancer Center
Hellenic Oncology Research Group
University of Chicago
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC